- •Effectiveness of high-efficacy therapy (HET) in multiple sclerosis (MS) is debated.
- •It is controversial whether HET is beneficial on brain volume loss (BVL) in MS.
- •Whether BVL differs with HET or low-efficacy therapy (LET) is investigated.
- •Disease activity was lower in Japanese patients with HET than LET over 2 years.
- •HET strongly reduced subcortical grey matter volume loss compared to LET.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
- Whole brain and grey matter volume of Japanese patients with multiple sclerosis.J. Neuroimmunol. 2017; 306: 68-75https://doi.org/10.1016/j.jneuroim.2017.03.009
- Thalamic atrophy in multiple sclerosis: a magnetic resonance imaging marker of neurodegeneration throughout disease.Ann. Neurol. 2018; 83: 223-234https://doi.org/10.1002/ana.25150
- Symmetrized percent change for treatment comparisons.Am. Stat. 2006; 60: 27-31https://doi.org/10.1198/000313006×90684
- The effect of disease-modifying drugs on brain atrophy in relapsing-remitting multiple sclerosis: a meta-analysis.PLoS ONE. 2016; 11e0149685https://doi.org/10.1371/journal.pone.0149685
- Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis.JAMA. 2019; 321: 175-187https://doi.org/10.1001/jama.2018.20588
- Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study.Neurology. 2020; 95: e1041-e1051https://doi.org/10.1212/WNL.0000000000010135
- Statistics Notes: what is a percentage difference?.BMJ. 2017; 358: 3663https://doi.org/10.1136/bmj.j3663
- Progression of regional grey matter atrophy in multiple sclerosis.Brain. 2018; 141: 1665-1677https://doi.org/10.1093/brain/awy088
- Measuring the thickness of the human cerebral cortex from magnetic resonance images.Proc. Natl. Acad. Sci. 2000; 97: 11050-11055
- Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.JAMA Neurol. 2019; : 1-6https://doi.org/10.1001/jamaneurol.2018.4905
- Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.Lancet Neurol. 2020; 19: 307-316https://doi.org/10.1016/S1474-4422(20)30067-3
- Comparison of brain atrophy in patients with multiple sclerosis treated with first- versus second-generation disease modifying therapy without clinical relapse.Eur. J. Neurol. 2020; 27: 2056-2061https://doi.org/10.1111/ene.14335
- Reproducibility of deep gray matter atrophy rate measurement in a large multicenter dataset.Am. J. Neuroradiol. 2018; 39: 46-53https://doi.org/10.3174/ajnr.A5459
- Lin4Neuro: a customized Linux distribution ready for neuroimaging analysis.BMC Med. Imaging. 2011; 25: 3https://doi.org/10.1186/1471-2342-11-3
- Multiple sclerosis in Japan appears to be a milder disease compared to the UK.J. Neurol. 2015; 262: 831-836
- Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis.Mult. Scler. J. 2020; 26: 312-321https://doi.org/10.1177/1352458519826364
- The effect of disease modifying therapies on brain atrophy in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.PLoS ONE. 2015; 10: 1-10https://doi.org/10.1371/journal.pone.0116511
- Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes.Mult. Scler. J. 2013; 19: 1175-1181https://doi.org/10.1177/1352458512473190
- Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis.Neurolgy. 2008; 71: 136-144https://doi.org/10.1212/01.wnl.0000316810.01120.05